Vivus Omits FDA Rejection in Press Release Touting a Study on It's Diet Pill

Here is a curious oversight. Anxious to see its Qnexa diet pill find its way to medicine cabinets, Vivus (VVUS) yesterday issued a press release touting a study in The Lancet medical journal that the drug demonstrated "significant weight loss and broad improvements in co-morbidities." The Lancet, in its own press release, suggested "this promising new treatment has additional metabolic benefits - improving blood pressure, lipids, glycaemia, and inflammatory markers." The upshot is that the study suggests the Qnexa diet pill could help overweight people lose...

Source:
http://article.wn.com/view/2011/04/13/Vivus_Omits_FDA_Rejection_in_Press_Release_Touting_a_Study_o/

current news stories abc news chicago news bbc health news articles latest international news